Monitoring the Virus Load Can Predict the Emergence of Drug‐Resistant Hepatitis B Virus Strains in Renal Transplantation Patients during Lamivudine Therapy
Citations Over TimeTop 10% of 2000 papers
Abstract
The development of resistant hepatitis B virus (HBV) strains during lamivudine treatment has been described repeatedly. To investigate whether the development of such resistant HBV strains can be predicted in an early phase of therapy, the HBV loads of 11 renal transplantation patients were screened at 3-month intervals by a quantitative HBV polymerase chain reaction (PCR) assay. Lamivudine resistance was detected by sequence analysis. Five patients developed resistance to lamivudine in the 12-15-month follow-up period. In all of them, a virus load of 1x103 HBV DNA copies still was detectable after 3 months of therapy. This was statistically significantly different from those patients who did not develop lamivudine resistance within the observation period, all of whom had no HBV DNA detectable after 3 months of treatment (P=.0022). Thus, virus load testing by use of a sensitive PCR assay allows the early prediction of the emergence of lamivudine-resistant HBV strains.
Related Papers
- → Heart Transplantation in Patients with Chronic Hepatitis B: Clinical Evolution, Molecular Analysis, and Effect of Treatment(2005)15 cited
- → Generation of Stable Cell Lines Expressing Lamivudine-Resistant Hepatitis B Virus for Antiviral-Compound Screening(2003)11 cited
- → Early detection and quantification of lamivudine-resistant hepatitis B virus mutants by fluorescent biprobe hybridization assay in lamivudine-treated patients(2006)4 cited
- → Treating acute hepatitis B†(2007)
- Strategy for prevention of HBV recurrence and reinfection in patients with hepatitis B related liver disease after liver transplantation.(2010)